The DOI matches its Crossref record; 62 of the 65 references it cites were found in a registry or an index; 14 of the 63 sources its claims cite were checked for support.
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
Open accessAbstract
Background Timely, accurate, and comprehensive estimates of SARS-CoV-2 daily infection rates, cumulative infections, the proportion of the population that has been infected at least once, and the effective reproductive number (R effective ) are essential for understanding the determinants of past infection, current transmission patterns, and a population's susceptibility to future infection with the same variant. Although several studies have estimated cumulative SARS-CoV-2 infections in select locations at specific points in time, all of these analyses have relied on biased data inputs that were not adequately corrected for. In this study, we aimed to provide a novel approach to estimating past SARS-CoV-2 daily infections, cumulative infections, and the proportion of the population infected, for 190 countries and territories from the start of the pandemic to Nov 14, 2021. This approach combines data from reported cases, reported deaths, excess deaths attributable to COVID-19, hospitalisations, and seroprevalence surveys to produce more robust estimates that minimise constituent biases. Methods We produced a comprehensive set of global and location-specific estimates of daily and cumulative SARS-CoV-2 infections through Nov 14, 2021, using data largely from Johns Hopkins University (Baltimore, MD, USA) and national databases for reported cases, hospital admissions, and reported deaths, as well as seroprevalence surveys identified through previous reviews, SeroTracker, and governmental organisations. We corrected these data for known biases such as lags in reporting, accounted for under-reporting of deaths by use of a statistical model of the proportion of excess mortality attributable to SARS-CoV-2, and adjusted seroprevalence surveys for waning antibody sensitivity, vaccinations, and reinfection from SARS-CoV-2 escape variants. We then created an empirical database of infection–detection ratios (IDRs), infection–hospitalisation ratios (IHRs), and infection–fatality ratios (IFRs). To estimate a complete time series for each location, we developed statistical models to predict the IDR, IHR, and IFR by location and day, testing a set of predictors justified through published systematic reviews. Next, we combined three series of estimates of daily infections (cases divided by IDR, hospitalisations divided by IHR, and deaths divided by IFR), into a more robust estimate of daily infections. We then used daily infections to estimate cumulative infections and the cumulative proportion of the population with one or more infections, and we then calculated posterior estimates of cumulative IDR, IHR, and IFR using cumulative infections and the corrected data on reported cases, hospitalisations, and deaths. Finally, we converted daily infections into a historical time series of R effective by location and day based on assumptions of duration from infection to infectiousness and time an individual spent being infectious. For each of these quantities, we estimated a distribution based on an ensemble framework that captured uncertainty in data sources, model design, and parameter assumptions. Findings Global daily SARS-CoV-2 infections fluctuated between 3 million and 17 million new infections per day between April, 2020, and October, 2021, peaking in mid-April, 2021, primarily as a result of surges in India. Between the start of the pandemic and Nov 14, 2021, there were an estimated 3·80 billion (95% uncertainty interval 3·44–4·08) total SARS-CoV-2 infections and reinfections combined, and an estimated 3·39 billion (3·08–3·63) individuals, or 43·9% (39·9–46·9) of the global population, had been infected one or more times. 1·34 billion (1·20–1·49) of these infections occurred in south Asia, the highest among the seven super-regions, although the sub-Saharan Africa super-region had the highest infection rate (79·3 per 100 population [69·0–86·4]). The high-income super-region had the fewest infections (239 million [226–252]), and southeast Asia, east Asia, and Oceania had the lowest infection rate (13·0 per 100 population [8·4–17·7]). The cumulative proportion of the population ever infected varied greatly between countries and territories, with rates higher than 70% in 40 countries and lower than 20% in 39 countries. There was no discernible relationship between R effective and total immunity, and even at total immunity levels of 80%, we observed no indication of an abrupt drop in R effective , indicating that there is not a clear herd immunity threshold observed in the data. Interpretation COVID-19 has already had a staggering impact on the world up to the beginning of the omicron (B.1.1.529) wave, with over 40% of the global population infected at least once by Nov 14, 2021. The vast differences in cumulative proportion of the population infected across locations could help policy makers identify the transmission-prevention strategies that have been most effective, as well as the populations at greatest risk for future i
Overview
CoChat Summary
TL;DR
Barber et al. estimated global, regional, and national daily and cumulative SARS-CoV-2 infections through Nov 14, 2021 by triangulating reported cases, hospitalisations, deaths, excess mortality, and seroprevalence data. They estimated 3.80 billion infections/reinfections and 3.39 billion individuals infected at least once, or 43.9% of the global population, with no clear herd immunity threshold observed.
Key findings
- Global daily infections fluctuated between 3 million and 17 million new infections per day from April, 2020, to October, 2021, peaking in mid-April, 2021, primarily due to surges in India.
- By Nov 14, 2021, there were an estimated 3.80 billion (95% UI 3.44–4.08) total SARS-CoV-2 infections and reinfections combined, and 3.39 billion (3.08–3.63) individuals, or 43.9% (39.9–46.9) of the global population, had been infected one or more times.
- South Asia had the most infections (1.34 billion [1.20–1.49]); sub-Saharan Africa had the highest infection rate (79.3 per 100 population [69.0–86.4]); the high-income super-region had the fewest infections (239 million [226–252]); southeast Asia, east Asia, and Oceania had the lowest infection rate (13.0 per 100 [8.4–17.7]). Over 70% of the population had been infected in 40 countries and under 20% in 39 countries.
- There was no discernible relationship between Reffective and total immunity, and even at total immunity levels of 80%, no abrupt drop in Reffective was observed, indicating no clear herd immunity threshold in the data.
Methods
- The study used a seven-step ensemble framework: corrected reported cases, hospitalisations, and deaths for reporting lags and under-reporting; adjusted 2817 seroprevalence survey datapoints for vaccination, waning antibody sensitivity, and reinfection from escape variants; and created empirical databases of infection–detection ratios (IDRs), infection–hospitalisation ratios (IHRs), and infection–fatality ratios (IFRs).
- Bayesian cascading regression models predicted IDR, IHR, and IFR by location and day using covariates including testing, universal health-care coverage, HAQ Index, age structure, and comorbidities; three daily infection series (cases/IDR, hospitalisations/IHR, deaths/IFR) were combined into a robust daily infection estimate, then summed to cumulative infections and the cumulative proportion infected at least once, and converted to Reffective.
- Estimates covered 190 countries and territories, subnational locations in ten countries, 21 regions, seven super-regions, and globally through Nov 14, 2021, with a 100-iteration ensemble to capture uncertainty in data sources, model design, and parameter assumptions.
Limitations
- The paper states that some seroprevalence surveys may be biased and corrections were inconsistent; the testing-capacity covariate cannot decline, so declines in effective testing may be missed; vaccination adjustments sometimes produced decreasing seroprevalence estimates, leading to exclusion of those data; interval IDR/IHR/IFR measures limit identification of short-term fluctuations; hospital admissions data were sparse in low- and middle-income settings; total COVID-19 mortality estimates had wide uncertainty intervals; and the model allowed a maximum of two infections per individual.
- The paper also notes that its analysis ends before the omicron wave and that omicron’s transmissibility and immune escape mean the findings should not be extrapolated to later periods.
- Evident from the text: the estimates depend on many modelling assumptions and covariates, and the lack of a clear herd immunity threshold may reflect confounding by seasonality, physical distancing, mask use, and new variant spread rather than immunity alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
7 Valid · 6 Not valid · 25 Not checked · 127 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This estimate did not take into account that some individuals could have been infected more than once with ancestral variants.31”
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Methods > Seroprevalence survey adjustments
What the sources say
- Disputedcites [31] Hansen CH Michlmayr D Gubbels SM Mølbak K Ethelberg S Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study Lancet 397 2021 1204 1212 33743221 PMC7969130 sourceExperimental — accuracy not yet measured
The Methods (Alternative cohort analysis; page unavailable) explicitly describe counting a new positive PCR test at least 90 days after an earlier positive test as a reinfection. The Results (page unavailable) report 138 reinfections and use them to estimate protection against repeat infection. Thus, the paper’s estimate did account for detected repeat infections, contrary to the claim. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
None of the sources cited for this claim have been checked yet.
In the paper
“Daily infections are also the crucial input into measuring the changing effective reproductive number (Reffective, the number of subsequent infections caused by a new infection).1, 2, 3”
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Introduction
What the sources say
- Could not verifycites [1] Bjørnstad ON Shea K Krzywinski M Altman N Modeling infectious epidemics Nat Methods 17 2020 455 456 32313223 sourceExperimental — accuracy not yet measured
Our copy of Bjørnstad et al. (Nature Methods 17, 453–456, 2020) is a deterministic SIR primer: it defines only the basic reproduction number R0 = β/γ as 'the expected number of secondary cases caused by a single primary infected individual introduced into a population with no prior immunity' (Abstract/body passage, p. 453–454) and discusses estimating SIR parameters shortly after a new disease appears to predict trajectory and needed reductions in R0 (closing passage). No passage anywhere in our copy mentions an effective reproduction number (Re), a time-varying/changing reproduction number, or daily infection counts (incidence) as the input for measuring one — searches for 'effective reproduction number', 'daily new infections case incidence data estimate R over time', and paraphrases returned only semantic neighbours, no exact hits. The claim's substantive point therefore cannot be checked against this source; the closest content (the R0 definition) is a different quantity with a fully-susceptible-population qualifier, not the Re-measurement assertion. (LLM, conf=0.72)
- Could not verifycites [2] Bjørnstad ON Shea K Krzywinski M Altman N The SEIRS model for infectious disease dynamics Nat Methods 17 2020 557 558 32499633 sourceExperimental — accuracy not yet measured
Our copy of the SEIRS column (Bjørnstad et al., Nat Methods 17:557–558, 2020) defines only the basic reproduction number R0 — 'the number of secondary cases for each infection in a completely susceptible population' — and its formula R0 = [σ/(σ+μ)]·[β/(γ+μ+αI)], plus the endemic relation S = 1/R0 (intro and Points of significance sections; p. 557–558). No passage introduces the effective reproductive number (Re) or states that daily infections/incidence are the input used to measure its change over time; I searched 'effective reproductive number Re', 'daily incidence case counts estimating time-varying reproduction number', and 'Rt susceptible fraction R0 S/N' with no hit. The paper is not contrary to the claim, it simply does not address it, so the attribution cannot be checked against this source. (LLM, conf=0.68)
- Not checked yetcites [3] Cintrón-Arias A Castillo-Chávez C Bettencourt LMA Lloyd AL Banks HT The estimation of the effective reproductive number from disease outbreak data Math Biosci Eng 6 2009 261 282 19364152 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Using the 718 seroprevalence surveys with age-specific detail, the COVID-19 Forecasting Team40 estimated the age pattern of the IFR.”
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Methods > Empirical estimates of the IDR, IHR, and IFR
What the sources say
- Supportedcites [40] COVID-19 Forecasting Team Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis Lancet 2022 published online Feb 24. 10.1016/S0140-6736(21)02867-1 PMC8871594 35219376 source
The Methods section, “Infection-fatality ratio by age,” reports 3012 age-specific observations from 718 seroprevalence surveys and says the team used a Bayesian meta-regression to estimate the non-linear age pattern of IFR. This directly supports the cited paraphrase. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Because reinfection can be common in settings where escape variants such as beta (B.1.351), gamma (P.1), and delta (B.1.617.2) are present,28, 29, 30”
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Methods > Seroprevalence survey adjustments
What the sources say
- Partly supportedcites [28] Sabino EC Buss LF Carvalho MPS Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Lancet 397 2021 452 455 33515491 PMC7906746 sourceExperimental — accuracy not yet measured
Our copy of Sabino et al. (2021) supports only part of what is attributed: the 'Third' paragraph (Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence) says lineages 'might evade immunity generated in response to previous infection', names B.1.351 and P.1 among three divergent lineages, and reports a single P.1-associated reinfection case in Manaus plus two reinfection cases with P.2 E484K — i.e., isolated case reports, not evidence that reinfection 'can be common'. The concluding paragraph likewise only says the new lineages 'may drive a resurgence... if they are associated with antigenic escape' and calls for monitoring reinfections, and the 'Second' paragraph actually cites a UK study finding reinfection 'uncommon up to 6 months'. Delta (B.1.617.2) is not addressed anywhere in our copy (searched: delta/B.1.617.2, reinfection frequency), so the claim's generality across beta, gamma and delta overstates this source. (LLM, conf=0.72)
- Not checked yetcites [29] Jolly B Rophina M Shamnath A Genetic epidemiology of variants associated with immune escape from global SARS-CoV-2 genomes bioRxiv 2021 published online Dec 26. 10.1101/2020.12.24.424332 (preprint). source
- Not checked yetcites [30] Lee J-S Kim SY Kim TS Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019 Clin Infect Dis 73 2021 e3002 e3008 33219681 PMC7890673 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other countries, such as Australia and New Zealand, have shown how early and effective lockdowns, combined with geographical isolation and travel restrictions, have kept transmission low throughout the study period.18, 55, 56”
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Discussion
What the sources say
- Partly supportedcites [18] Kontis V Bennett JE Rashid T Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries Nat Med 26 2020 1919 1928 33057181 PMC7615092 sourceExperimental — accuracy not yet measured
The Discussion says New Zealand introduced movement restrictions or lockdowns early and kept cases low; it also places both New Zealand and Australia among countries without a detectable rise in all-cause mortality. It does not establish that geographical isolation and travel restrictions, combined with early lockdowns, kept transmission low in both countries throughout the study period. (LLM, conf=0.86)
- Partly supportedcites [55] Adekunle A Meehan M Rojas-Alvarez D Trauer J McBryde E Delaying the COVID-19 epidemic in Australia: evaluating the effectiveness of international travel bans Aust N Z J Public Health 44 2020 257 259 32697418 PMC7405030 sourceExperimental — accuracy not yet measured
The Results and Discussion report that Australia's China travel ban delayed widespread local transmission by about a month. The paper does not establish that lockdowns or geographical isolation kept transmission low in Australia and New Zealand throughout the study period; its Abstract instead says stronger domestic controls were needed in Australia. (LLM, conf=0.88)
- Partly supportedcites [56] Jefferies S French N Gilkison C COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study Lancet Public Health 5 2020 e612 e623 33065023 PMC7553903 sourceExperimental — accuracy not yet measured
The Discussion reports that New Zealand’s early lockdown and border controls reduced transmission and helped maintain very low case numbers during the study period. It does not establish the same account for Australia; it instead names Australia among countries with slower lockdown implementation. The paper discusses New Zealand’s island-state border advantage, but does not separately measure the effect of geographical isolation. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
97 more claims · 2 with their cited sources checked
Create a free account to see all 165 claims and to verify the 42 references still open.
- Probably not a substantial claim. 36
- It may state two separate claims as one. 36
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The emergence and spread of COVID-19 follows a similar pattern of regional heterogeneity that is common among many leading communicable causes of death, with higher rates of infection and increased fatalities occurring in lower-resource settings.6, 16, 17”
From Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Locations with strained and under-resourced health systems faced overwhelming structural challenges in securing swift and sufficient supplies of vaccine, which compromised vaccine delivery to high-risk populations,29 and further affected progress in responding to the burden imposed by the pandemic in under-resourced locations in 2021.25”
From Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, data on COVID-19 outcomes (eg, cases, deaths, hospital admissions, and seroprevalence) were of highly variable quality and completeness, which required novel methods for standardisation.23, 25, 26”
From Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [25]
In the citing paper
“older individuals with co-infection, particularly those who were undiagnosed with tuberculosis at the beginning of the pandemic, might have died from COVID-19.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Results
“5570 (4120–7780) | 14·1 (10·4–19·7) | 6·2% (1·7–16·1)”
§ Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis > Discussion
“Seventh, our model permitted a maximum of two infections per individual”
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Self-citationAn interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing
Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Abeler-Dörner, L., Parker, M., Bonsall, D., & Fraser, C. (2020) · Science · doi:10.1126/science.abb6936 · Cited by 2,512
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Wang, H., Paulson, K. R., Pease, S. A., Watson, S., Comfort, H., Zheng, P., Aravkin, A. Y., Bisignano, C., Barber, R. M., Alam, T., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02796-3 · Cited by 2,069
Self-citationGuidelines for accurate and transparent health estimates reporting: the GATHER statement
Stevens, G. A., Alkema, L., Black, R. E., Boerma, J. T., Collins, G. S., Ezzati, M., Grove, J. T., Hogan, D. R., Hogan, M. C., Horton, R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30388-9 · Cited by 1,798
Self-citationGBD 2010: design, definitions, and metrics
Murray, C. J., Ezzati, M., Flaxman, A. D., Lim, S., Lozano, R., Michaud, C., Naghavi, M., Salomon, J. A., Shibuya, K., Vos, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61899-6 · Cited by 1,103
Self-citationEstimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
Cited by
Ferrari, A. J., Santomauro, D. F., Aali, A., Abate, Y. H., Abbafati, C., Abbastabar, H., Abd ElHafeez, S., Abdelmasseh, M., Abd-Elsalam, S., Abdollahi, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00757-8 · Cited by 5,112
Self-citationNaghavi, M., Ong, K. L., Aali, A., Ababneh, H. S., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasian, M., Abbasi-Kangevari, M., Abbastabar, H., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00367-2 · Cited by 2,889
“6,16,17 Although heterogeneity in COVID-19 outcomes in 2020 and 2021 varied by the income status of a country or territory, outcomes were also directly related to age, government actions to close borders, and the implementation of transmission-reduction policies.”
BackgroundSelf-citationCollaborators, G. B. O. D. L. C., Wulf Hanson, S., Abbafati, C., Aerts, J. G., Al-Aly, Z., Ashbaugh, C., Ballouz, T., Blyuss, O., Bobkova, P., Bonsel, G., et al. (2022) · JAMA · doi:10.1001/jama.2022.18931 · Cited by 970
Self-citationThe Global Burden of Disease Study at 30 years
Murray, C. J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01990-1 · Cited by 856
Self-citationLong COVID science, research and policy
Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A., & Topol, E. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03173-6 · Cited by 538
Metadata
- Authors
- Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., Aravkin, A. Y., Bang-Jensen, B. L., Castro, E., Chakrabarti, S., Cogen, R. M., Combs, E., Comfort, H., Cooperrider, K., Dai, X., Daoud, F., Deen, A., Earl, L., Erickson, M., Ewald, S. B., Ferrari, A. J., Flaxman, A. D., Frostad, J. J., Fullman, N., Giles, J. R., Guo, G., He, J., Helak, M., Hulland, E. N., Huntley, B. M., Lazzar-Atwood, A., LeGrand, K. E., Lim, S. S., Lindstrom, A., Linebarger, E., Lozano, R., Magistro, B., Malta, D. C., Månsson, J., Mantilla Herrera, A. M., Mokdad, A. H., Monasta, L., Naghavi, M., Nomura, S., Odell, C. M., Olana, L. T., Ostroff, S. M., Pasovic, M., Pease, S. A., Reiner Jr, R. C., Reinke, G., Ribeiro, A. L. P., Santomauro, D. F., Sholokhov, A., Spurlock, E. E., Syailendrawati, R., Topor-Madry, R., Vo, A. T., Vos, T., Walcott, R., Walker, A., Wiens, K. E., Wiysonge, C. S., Worku, N. A., Zheng, P., Hay, S. I., Gakidou, E., & Murray, C. J. L.
- Corresponding author
- Barber, Ryan M
- ORCID
- Barber, Ryan M
- Sorensen, Reed J D
- Pigott, David M
- Carter, Austin
- Collins, James K
- Abbafati, Cristiana
- Adolph, Christopher
- Allorant, Adrien
- Aravkin, Aleksandr Y
- Bang-Jensen, Bree L
- Chakrabarti, Suman
- Dai, Xiaochen
- Daoud, Farah
- Ewald, Samuel B
- Ferrari, Alize J
- Flaxman, Abraham D
- Fullman, Nancy
- Guo, Gaorui
- He, Jiawei
- Hulland, Erin N
- LeGrand, Kate E
- Lim, Stephen S
- Lindstrom, Akiaja
- Lozano, Rafael
- Magistro, Beatrice
- Mokdad, Ali H
- Monasta, Lorenzo
- Naghavi, Mohsen
- Nomura, Shuhei
- Pasovic, Maja
- Pease, Spencer A
- Reinke, Grace
- Santomauro, Damian F
- Sholokhov, Aleksei
- Spurlock, Emma E
- Vo, Anh Truc
- Vos, Theo
- Walcott, Rebecca
- Wiens, Kirsten E
- Wiysonge, Charles Shey
- Hay, Simon I
- Gakidou, Emmanuela
- Murray, Christopher J L
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 399
- Issue
- 10344
- Pages
- 2351-2380
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8993157
- OpenAlex
- W4223443877
- Semantic Scholar
- 6e85baaa79fcc5d72aa4afd7107b35833323a529
- Cited by
- 298
- References
- 65
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 80 · 2023: 105 · 2022: 66
- FWCI
- 41.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Funders
- Queensland Government
- Queensland Health
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (310679/2016-8, 465518/2014-1)
- National Health and Medical Research Council (APP1121516)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (PPM-00428-17, RED-00081-16)
- South African Medical Research Council
- National Science Foundation (2031096)
- Ministry of Education, Culture, Sports, Science and Technology
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.507149/2020-00)
- New York State Department of Health
- Bill and Melinda Gates Foundation
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
- Keywords
- SARS-CoV-2, COVID-19 pandemic, cumulative infections, infection fatality rate, excess mortality, seroprevalence, effective reproduction number, reinfection, escape variants, vaccination, global estimates, country-level estimates, time series forecasting, SARS-CoV-2 variants
- MeSH terms
- COVID-19, SARS-CoV-2, Humans, Seroepidemiologic Studies, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00484-6
- The paper
- Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., Aravkin, A. Y., Bang-Jensen, B. L., Castro, E., Chakrabarti, S., Cogen, R. M., Combs, E., Comfort, H., Cooperrider, K., Dai, X., . . . Murray, C. J. L. (2022). Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. The Lancet. https://doi.org/10.1016/s0140-6736(22)00484-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.